MSACL 2025 Industry Workshop Presentation *This Podium Presentation is occuring in the context of an Industry Workshop that starts at the time below. Its actual start time may be up to 40 minutes later, depending on order of presentation if there are multiple presentations planned by the workshop host. Workshop Host: Thermo Fisher Scientific Day: Tuesday September 23 Time: 12:45* Location: Montreal 6-8 (Track 5)

New Frontiers in LC-MS – developing an efficient discovery to validation pipeline
	Patrick Vanderboom, Ph.D. Mayo Clinic
Presenter Bio: Dr. Patrick Vanderboom is the director of clinical informatics for the Division of Clinical Biochemistry and Immunology at Mayo Clinic in Rochester MN. Dr. Vanderboom also serves as the co-director of the Antibody Immunology Laboratory and the translational director for proteomics in the Advanced Diagnostics Laboratory.
	Qin Fu, PhD Thermo Fisher Scientific
Presenter Bio: Qin Fu joined the Chromatography and Mass Spectrometry group at Thermo Fisher since 2024. Before that, she was a member of Jennifer Van Eyk’s research group at Cedars Sinai and Johns Hopkins, where she developed workflows for automated MS sample preparation, multiplexed targeted MS assays, quantitative DIA analysis, and biomarker discovery and validation. She received her PhD from the University of Minnesota and post-doctoral training at UCSF.

Significant efforts have been dedicated towards discovering, developing, and validating biomarkers for disease diagnosis, prognosis, and therapy guidance. Achieving these goals requires laboratories to produce reproducible results through streamlined workflows and the adoption of innovative technologies. However, the complexity of study designs, labor-intensive sample preparation, and the intricacies of LC-MS workflows have limited the number of robust validation studies for newly identified biomarkers.

In today’s workshop, our first speaker will discuss real-world analysis of neurodegenerative disease pathology markers (i.e.: ALS biomarkers) from extracellular vesicles (EVs) and the utilization of novel, breakthrough mass spectrometry technologies driving robust biomarker identification and translation towards clinical settings. Our second workshop speaker will present a high-throughput quantitative proteomics workflow, highlighting practical guidelines and efficiencies across the workflow towards clinical-grade biomarker candidates.